Personalized medicine for non-small-cell lung cancer: Implications of recent advances in tissue acquisition for molecular and histologic testing

Clinical Lung Cancer

Volumn 13, Issue 5, 2012, Pages 334-339

  Moreira, Andre L ^a   Thornton, Raymond H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Biopsy; Histopathology; Lung cancer; Molecular diagnosis; Tissue procurement

Indexed keywords

AFATINIB; CRIZOTINIB; DACOMITINIB; DOCETAXEL; ERLOTINIB; GEFITINIB; PEMETREXED;

ADENOCARCINOMA; ADVANCED CANCER; CLINICAL ASSESSMENT; ENDOBRONCHIAL ULTRASONOGRAPHY; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; ONCOGENE K RAS; PLEURA EFFUSION; POLYMERASE CHAIN REACTION; REVIEW; SQUAMOUS CELL CARCINOMA; TRANSBRONCHIAL ASPIRATION; TRANSTHORACIC ASPIRATION;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; SPECIMEN HANDLING; TISSUE AND ORGAN PROCUREMENT;

EID: 84865467600     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.01.004     Document Type: Review

References (72)

1. W.D. Travis, N. Rekhtman, G.J. Riley Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift J Thorac Oncol 5 2010 411 414
2. W.D. Travis, N. Rekhtman Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing Semin Respir Crit Care Med 32 2011 22 31
3. D.H. Johnson, L. Fehrenbacher, W.F. Novotny Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2004 2184 2191
4. AVASTIN® (bevacizumab) solution for intravenous infusion [package insert] 2011 Genentech Inc San Francisco, CA
5. G. Scagliotti, T. Brodowicz, F.A. Shepherd Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer J Thorac Oncol 6 2011 64 70
6. G. Scagliotti, N. Hanna, F. Fossella The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies Oncologist 14 2009 253 263
7. Alimta® (pemetrexed disodium) [package insert] 2009 Eli Lilly Indianapolis, IN
8. M. Ladanyi, W. Pao Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond Mod Pathol 21 suppl 2 2008 S16 S22
9. T.S. Mok, Y.L. Wu, S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
10. A.T. Shaw, B.Y. Yeap, M. Mino-Kenudson Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK J Clin Oncol 27 2009 4247 4253
11. V.L. Keedy, S. Temin, M.R. Somerfield American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy J Clin Oncol 29 2011 2121 2127
12. L. Horn, W. Pao EML4-ALK: honing in on a new target in non-small-cell lung cancer J Clin Oncol 27 2009 4232 4235
13. Non-Small cell National Comprehensive Cancer Network Clinical Practice Guidelines in Oncologyv.3.2011 [Website] http://www.nccn.org/professionals/ physician-gls/PDF/nscl.pdf Accessed: May 21, 2011
14. G. Bepler, M. Begum, G.R. Simon Molecular analysis-based treatment strategies for Non-Small cell lung cancer Cancer Contr 15 2008 130 139
15. M. Cobo, D. Isla, B. Massuti Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in Non-Small-cell lung cancer J Clin Oncol 25 2007 2747 2754
16. F.R. Hirsch, M. Varella-Garcia, P.A. Bunn Jr Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced Non-Small-cell lung cancer J Clin Oncol 24 2006 5034 5042
17. Z. Li, S. Zhou, L. Zhang RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced NSCLC patients treated with cisplatin-based chemotherapy J Thorac Oncol 4 2009 S915 S916
18. ™) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung J Thorac Oncol 4 2009 S283 S284 (abstract PRS.4)
19. M. Maemondo, A. Inoue, K. Kobayashi Gefitinib or chemotherapy for Non-Small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
20. P.A. Janne, K. Reckamp, M. Koczywas A phase 2 trial of PF-00299804 (PF299), an oral irreversible HER tyrosine kinase inhibitor (TKI), in patients (pts) with advanced NSCLC after failure of prior chemotherapy and erlotinib: preliminary efficacy and safety results J Thorac Oncol 4 2009 S293 S294 (abstract A3.1)
21. V.A. Miller, V. Hirsh, J. Cadranel Phase IIB/III double-blind randomized trial of afatinib (BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2) + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib (LUX-LUNG 1) Ann Oncol 21 2010 viii1 (abstract LBA1)
22. Y. Bang, E.L. Kwak, A.T. Shaw Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) J Clin Oncol 28 2010 3 5
23. D.R. Camidge, Y. Bang, A.J. Iafrate Clinical activity of crizotinib (PF-02341066), in ALK-positive patients with non-small cell lung cancer (NSCLC) Ann Oncol 21 2010 viii123 (abstract 366PD)
24. Food and Drug Administration FDA News release FDA approves Xalkori with companion diagnostic for a type of late-stage lung cancer http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm269856.htm Accessed: August 29, 2011
25. D.S. Schrump, N.K. Altorki, C.L. Henschke Non-Small cell lung cancer V.T. DeVita, S. Hellman, S.A. Rosenberg, Cancer: Principles and Practices 2005 Lippincott Williams & Wilkins Philadelphia, PA 753 810
26. M.T. Rivera, A.C. Mehta Initial diagnosis of lung cancer: ACCP Evidence-based Clinical Practice Guidelines, 2nd ed. Chest 132 2007 131S 148S
27. A. Hasanovic, N. Rekhtman, C.S. Sigel Advances in fine needle aspiration cytology for the diagnosis of pulmonary carcinoma Pathol Res Int 2011 2011 897292
28. Y.C. Cheung, J.W. Chang, J.J. Hsieh Adequacy and complications of computed tomography-guided core needle biopsy on non-small cell lung cancers for epidermal growth factor receptor mutations demonstration: 18-gauge or 20-gauge biopsy needle Lung Cancer 67 2010 166 169
29. P.R. Geraghty, S.T. Kee, G. McFarlane CT-guided transthoracic needle aspiration biopsy of pulmonary nodules: needle size and pneumothorax rate Radiology 229 2003 475 481
30. E.A. Kazerooni, F.T. Lim, A. Mikhail Risk of pneumothorax in CT-guided transthoracic needle aspiration biopsy of the lung Radiology 198 1996 371 375
31. B.T. Uskl, H. Trker, M. Gke CT-guided transthoracic fine needle aspiration of pulmonary lesions: accuracy and complications in 134 cases Tuberk Toraks 57 2009 177 185
32. J. Eckardt, K.E. Olsen, P.B. Licht Endobronchial ultrasound-guided transbronchial needle aspiration of undiagnosed chest tumors World J Surg 34 2010 1823 1827
33. N. Kothary, L. Lock, D.Y. Sze Computed tomography-guided percutaneous needle biopsy of pulmonary nodules: impact of nodule size on diagnostic accuracy Clin Lung Cancer 10 2009 360 363
34. J.E. Lee, H.Y. Kim, K.Y. Lim Endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of lung cancer Lung Cancer 70 2010 51 56
35. J. Cadranel, G. Zalcman, L. Sequist Genetic profiling and epidermal growth factor receptor-directed therapy in Non-Small cell lung cancer Eur Respir J 37 2011 183 193
36. C.S. Sigel, A.L. Moreira, W.D. Travis Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens J Thorac Oncol 6 2011 1849 1856
37. H. Li, P.M. Boiselle, J.O. Shepard Diagnostic accuracy and safety of CT-guided percutaneous needle aspiration biopsy of the lung: comparison of small and large pulmonary nodules AJR Am J Roentgenol 167 1996 105 109
38. S.B. Solomon, M.F. Zakowski, W. Pao Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis AJR Am J Roentgenol 194 2010 266 269
39. O.C. Schuurbiers, M.G. Looijen-Salamon, M.J. Ligtenberg A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates J Thorac Oncol 5 2010 1664 1667
40. T.S. Weiser, K. Hyman, J. Yun Electromagnetic navigational bronchoscopy: a surgeon's perspective Ann Thorac Surg 85 2008 S797 S801
41. M.E. Hammond, D.F. Hayes, A.C. Wolff Clinical notice for American Society of Clinical OncologyCollege of American pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer J Clin Oncol 29 2011 e458
42. S.L. Edwards, C. Roberts, M.E. McKean Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category J Clin Pathol 53 2000 537 540
43. S.H. Ou, J.A. Zell Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies J Thorac Oncol 4 2009 1202 1211
44. N. Rekhtman Neuroendocrine tumors of the lung: an update Arch Pathol Lab Med 134 2010 1628 1638
45. S. Khayyata, S. Yun, T. Pasha Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens Diagn Cytopathol 37 2009 178 183
46. P.S. Loo, S.C. Thomas, M.C. Nicolson Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens J Thorac Oncol 5 2010 442 447
47. S. Mukhopadhyay, A.L. Katzenstein Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6 Am J Surg Pathol 35 2011 15 25
48. A.G. Nicholson, D. Gonzalez, P. Shah Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis J Thorac Oncol 5 2010 436 441
49. L. Righi, P. Graziano, A. Fornari Immunohistochemical subtyping of Non-Small cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation Cancer 117 2011 3416 3423
50. G. Rossi, M. Papotti, M. Barbareschi Morphology and a limited number of immunohistochemical markers may efficiently subtype non-small-cell lung cancer J Clin Oncol 27 2009 e141 e142
51. J. Terry, S. Leung, J. Laskin Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples Am J Surg Pathol 34 2010 1805 1811
52. N. Rekhtman, S.M. Brandt, C.S. Sigel Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing J Thorac Oncol 6 2011 451 458
53. W.D. Travis, E. Brambilla, M. Noguchi International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma J Thorac Oncol 6 2011 244 285
54. N. Rekhtman, D.C. Ang, C.S. Sima Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens Mod Pathol 10 2011 1348 1359
55. J.A. Bishop, J. Teruya-Feldstein, W.H. Estra p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma Mod Pathol 2011 1038/modpath.2011.173 [Epub ahead of print]
56. L. Boldrini, S. Gisfredi, S. Ursino Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis J Thorac Oncol 2 2007 1086 1090
57. A. Horiike, H. Kimura, K. Nishio Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer Chest 131 2007 1628 1634
58. J.H. Smouse, E.S. Cibas, P.A. Jnne EGFR mutations are detected comparably in cytologic and surgical pathology specimens of Non-Small cell lung cancer Cancer 117 2009 67 72
59. C.M. Chen, J.W. Chang, Y.C. Cheung Computed tomography-guided core-needle biopsy specimens demonstrate epidermal growth factor receptor mutations in patients with Non-Small-cell lung cancer Acta Radiol 49 2008 991 994
60. M. Alsharif, J. Carlo-Demovich, C. Massey Telecytopathology for immediate evaluation of fine-needle aspiration specimens Cancer Cytopathol 118 2010 119 126
61. O.O. Burlingame, K.O. Kesse, S.G. Silverman On-site adequacy evaluations performed by cytotechnologists: correlation with final interpretations of 5241 image-guided fine needle aspiration biopsies Cancer Cytopathol 2011 10.1002/cncy.20184 [Epub ahead of print]
62. G. da Cunha Santos, M.A. Saieg, W. Geddie EGFR gene status in cytological samples of Non-Small cell lung carcinoma: controversies and opportunities Cancer Cytopathol 119 2011 80 91
63. G. Baloglu, A. Haholu, Z. Kucukodaci The effects of tissue fixation alternatives on DNA content: a study on normal colon tissue Appl Immunohistochem Mol Morphol 16 2008 485 492
64. L. Guillou, J. Coindre, G. Gallagher Detection of the synovial sarcoma translocation t. X; 18 [SYT and SSX] in paraffin-embedded tissues using reverse transcriptase-polymerase chain reaction: a reliable and powerful diagnostic tool for pathologists A molecular analysis of 221 mesenchymal tumors fixed in different fixatives Hum Pathol 32 2001 105 112
65. A.C. Wolff, M.E. Hammond, J.N. Schwartz American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med 131 2007 18 43
66. ™ automated cell block versus traditional cell block preparation: a comparison of morphologic features and immunohistochemical staining Diagn Cytopathol 39 2010 730 736
67. M.G. Raso, I.I. Wistuba Molecular pathogenesis of early-stage non-small cell lung cancer and a proposal for tissue banking to facilitate identification of new biomarkers J Thorac Oncol 2 2007 S128 S135
68. M.H. Lawson, D.M. Rassl, N.M. Cummings Tissue banking of diagnostic lung cancer biopsies for extraction of high quality RNA J Thorac Oncol 5 2010 956 963
69. G. da Cunha Santos, N. Liu, M.S. Tsao Detection of EGFR and KRAS mutations in fine-needle aspirates stored on Whatman FTA cards: is this the tool for biobanking cytological samples in the molecular era? Cancer Cytopathol 118 2010 450 456
70. G.D. Smith, B.E. Chadwick, C. Willmore-Payne Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis J Clin Pathol 61 2008 487 493
71. AstraZeneca AstraZeneca announces plan to withdraw US NDA for Iressa; current US patients have continued access http://www.astrazeneca-us.com/about- astrazeneca-us/newsroom/all/12045633?itemId=12045633 Accessed: July 12, 2011
72. Tarceva® (erlotinib tablets) [package insert]. South San Francisco, CA: Genentech, Inc.